Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Colorectal Cancer
This study is no longer recruiting patients.
Sponsored by: | National Cancer Institute (NCI) M.D. Anderson Cancer Center
|
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of 6-hydroxymethylacylfulvene in treating patients with metastatic colorectal cancer.
Condition | Treatment or Intervention | Phase |
---|---|---|
recurrent colon cancer Stage IV rectal cancer adenocarcinoma of the colon adenocarcinoma of the rectum recurrent rectal cancer stage IV colon cancer |
Drug: -hydroxymethylacylfulvene |
Phase II |
MedlinePlus related topics: Colorectal Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of 6-Hydroxymethylacylfulvene (MGI-114) for Metastatic Adenocarcinoma of the Colon or Rectum
Study start: August 1998
OBJECTIVES: I. Assess the antitumor activity of 6-hydroxymethylacylfulvene (MGI-114) when given daily for 5 days every 28 days to patients with metastatic adenocarcinoma of the colon or rectum.
II. Evaluate the qualitative and quantitative toxicities of MGI-114 given on this schedule in this patient population.
PROTOCOL OUTLINE: Patients receive 6-hydroxymethylacylfulvene (MGI-114) IV over 5 minutes daily for 5 consecutive days. Courses are repeated every 28 days. The minimum treatment period is 2 courses. Treatment continues indefinitely in the absence of unacceptable toxic effects or disease progression.
Patients are followed at the end of every other course while on the study, and then every 3 months thereafter until death.
PROJECTED ACCRUAL: A total of 18-35 patients will be accrued for this study within 6-10 months.
Eligibility
Ages Eligible for Study: 18 Years and above
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
Location Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |